404 Error

INVEGA^® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). The efficacy of INVEGA^® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (12-17 years of age), as well as one maintenance trial in adults.

INVEGA^® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressant therapy in adults. The efficacy of INVEGA^® in schizoaffective disorder was established in two 6-week trials in adults.

Page not found

We apologize. The page that you requested is not available.

To help find what you are looking for, please use the search box above or refer to our Site Map for an overview of all of the information available on this site.

cp-33119v3

This site is published by Janssen Pharmaceuticals, Inc. , which is solely responsible for its contents. The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.

This information is intended for the use of patients and caregivers in the United States and Puerto Rico only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Capitalized product names are trademarks of Janssen Pharmaceuticals, Inc.

Last updated December 19, 2019